Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 16/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR1E | P28566 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169215 | 0.90 | CETP (0.42) | CETPTACR1 | |
| SCHEMBL4186620 | 0.90 | CETP (0.39) | CETPTACR1 | |
| SCHEMBL4188238 | 0.90 | CETP (0.39) | CETPTACR1HTR2AHTR1AHTR1D | |
| SCHEMBL4183979 | 0.89 | CETP (0.42) | CETPTACR1 | |
| SCHEMBL4176264 | 0.88 | CETP (0.46) | CETPTACR1 | |
| SCHEMBL4180457 | 0.88 | CETP (0.50) | CETPHTR7 | |
| SCHEMBL1601013 | 0.88 | CETP (0.45) | CETPTACR1 | |
| SCHEMBL4176272 | 0.87 | CETP (0.44) | CETP | |
| SCHEMBL2880081 | 0.87 | CETP (0.45) | CETPTACR1 | |
| SCHEMBL4179601 | 0.86 | CETP (0.41) | CETPTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | APOB, LDLR, CETP | CETP 3/4885TACR1 2334/4885HTR2A 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.